Nguyen AnhCo 4

What Happened

• Nguyen AnhCo, President and CEO (also a director) of Atara Biotherapeutics, received a grant of 81,100 restricted stock units (RSUs) on 2026-03-09. The transaction is reported as an award/acquisition (code A) at $0.00 per share (typical for RSU grants, not a market purchase).

Key Details

• Transaction date: 2026-03-09; Form 4 filed: 2026-03-11 (filed within the normal 2-business-day reporting window).
• Amount: 81,100 RSUs granted; reported price: $0.00 (award).
• Shares owned after transaction: not specified in the provided data.
• Footnote (vesting): RSUs vest 1/8 of the total on the second Quarterly Vesting Date after March 9, 2026, then 1/8 on each of the next seven Quarterly Vesting Dates (Quarterly Vesting Dates = Mar 1, May 15, Aug 15, Nov 15; if a date is a weekend/holiday, the next business day). Vesting is subject to continuous employment.
• No indication of a sale, exercise, 10b5-1 plan, tax-withholding sale, or late filing in the provided filing.

Context

• RSU grants are deferred equity awards that convert to shares as they vest; receiving RSUs is not an immediate market purchase or sale. Vesting schedule and continued employment determine when the insider actually receives shares and any taxable event.